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UMP synthase (UMPS) catalyzes the last two steps
of de novo pyrimidine nucleotide synthesis and is
a potential cancer drug target. The C-terminal do-
main of UMPS is orotidine-50-monophosphate de-
carboxylase (OMPD), a cofactor-less yet extremely
efficient enzyme. Studies of OMPDs from micro-
organisms led to the proposal of several noncovalent
decarboxylation mechanisms via high-energy inter-
mediates. We describe nine crystal structures of
human OMPD in complex with substrate, product,
and nucleotide inhibitors. Unexpectedly, simple com-
pounds can replace the natural nucleotides and
induce a closed conformation of OMPD, defining a
tripartite catalytic site. The structures outline the re-
quirements drugs must meet to maximize therapeutic
effects andminimize cross-species activity. Chemical
mimicry by iodide identified a CO2 product binding
site. Plasticity of catalytic residues and a covalent
OMPD-UMP complex prompt a reevaluation of the
prevailing decarboxylation mechanism in favor of
covalent intermediates. This mechanism can also ex-
plain the observed catalytic promiscuity of OMPD.
INTRODUCTION
Nucleotide biosynthesis in mammalian cells largely relies on the
salvage pathway, while the de novo biosynthesis is predominant
in rapidly dividing cells. Consequently, inhibitors of the enzymes
involved in de novo nucleotide biosynthesis are used to treat
neoplastic and autoimmune diseases or as immuno suppres-
sants to prevent transplanted organ rejection (Christopherson
et al., 2002; Chu et al., 2003). In higher eukaryotes, UMP syn-
thase (UMPS) harbors both enzymatic activities for the penulti-
mate and the last step of pyrimidine nucleotide biosynthesis on
a single polypeptide chain (Figure 1A). Orotate phosphoribosyl
transferase (OPRT) catalyzes formation of orotidine-50-mono-
phosphate (OMP) from phosphoribosyl pyrophosphate and
orotic acid. In the last step, OMP is decarboxylated to UMP by
OMP decarboxylase (OMPD) (Figure 1A). Inactivity of UMPS82 Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reresults in orotic aciduria, an autosomal recessive disease that
is characterized by large amounts of orotic acid in the urine.
In contrast to other decarboxylases, OMPD does not need any
cofactors or metal ions and is a remarkably efficient enzyme. The
half-life of the spontaneous decarboxylation of OMP to UMP has
been estimated at 78 million years, but Saccharomyces cerevi-
siae OMPD accelerates this reaction by a factor of 1.4$1017
(Radzicka and Wolfenden, 1995). This enormous rate enhance-
ment (kcat/kuncat) is paralleled by very few enzymes, most notably
sweet potato b-amylase and fumarase, which display kcat/kuncat
values of 7.2$1017 and 3.5$1015, respectively (Fersht, 1999). De-
spite a large body of structural and kinetic data of OMPDs from
several micro-organisms, the enzymatic mechanism is still a mat-
ter of debate (Miller and Wolfenden, 2002). Among the proposed
mechanisms are covalent (Silverman and Groziak, 1982), con-
certed (Appleby et al., 2000), and noncovalent mechanisms.
The latter postulate high-energy intermediates such as ylide
zwitterions (Beak and Siegel, 1976) and nitrenes (Lee and
Houk, 1997; Lee et al., 2001).
We have characterized human OMPD and determined crystal
structures in complex with several nucleotides and nucleotide
analogs. Human OMPD is almost as catalytically efficient as its
counterparts from micro-organisms. The structures delineate
the active site plasticity and probe the requirements for drug de-
sign and catalysis. We find that 5-halo-UMP derivatives are weak
OMPD inhibitors and the active site of OMPD is sufficiently flex-
ible to accommodate substituents with different steric require-
ments. 6-iodo-UMP is a potent inhibitor of human OMPD, cova-
lently modifying a crucial catalytic lysine, which demonstrates
that lysine might act as both a Brønsted acid/base and a nucleo-
phile during catalysis. By using a catalytically inactive mutant of
OMPD, unusual distortions of the substrate and a substrate an-
alog were observed that seem to be genuine to OMPDs and
might represent catalytic intermediates.
RESULTS
Characterization of OMPD
The OMPD domain from human UMP synthase comprises
the C-terminal 256 residues (numbered 224–480 in human UMP
synthase). In a continuous enzyme assay monitoring the decrease
of A285 upon OMP decarboxylation (Figures 1B and Figure S1, see
the Supplemental Data available with this article online), wild-type
OMPD shows Michaelis-Menten behavior with KM = 16.6 ± 1.7 mMserved
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1 (Figure 1C). These values are over one order of
magnitude lower than the parameters determined forS. cerevisiae
OMPD (KM = 0.7mM and kcat = 44 s
1). As a result, human OMPD is
not as proficient asS.cerevisiaeOMPD but still accelerates the un-
catalyzed OMP decarboxylation by fourteen orders of magnitude.
Since in human UMP synthase OMPD is present with OPRT on the
Figure 1. UMPS Domain Structure and
OMPD Biochemistry
(A) Reaction catalyzed by OMPD.
(B) Turnover of OMP substrate by wild-type OMPD
(black) is abolished in the Asp312Asn mutant (red).
If the detection limit of the assay is assumed to be
5% of the total signal over 4000 s, the Asp312Asn
mutant is at least 1300-fold less active than the
wild-type.
(C) Michaelis-Menten kinetics of wild-type OMPD
at 25C.
(D) OMPD is an obligatory dimer of high affinity.
same polypeptide, substrate channeling
from OPRT to OMPD could occur that
might increase the overall reaction effi-
ciency.
Human OMPD is a dimer in solution, as
verified by gel permeation chromatogra-
phy. For S. cerevisiae OMPD, the dimeric
state is required for enzymatic activity
(the monomer is inactive), and the equi-
librium dissociation constant is 0.25 mM
(Porter and Short, 2000). Over a concen-
tration range of 3.5 mM–16 nM OMPD enzymatic activity remains
linear, consistent with the dimer being stable at nanomolar
concentrations (Figure 1D). Thus, the human OMPD dimer is re-
sistant to dissociation as strong dilution does not abolish activity
and the equilibrium dissociation constant for the OMPD dimer is
in the range Kd% 16 nM.
Figure 2. Architecture of the OMPD Dimer
and the Active Site
(A) One monomer is colored in gray, and the other
according to secondary structure. UMP is shown
as a stick model and the loop closing onto the ac-
tive site is drawn in green. This loop is disordered
in the electron density of the apo-OMPD structure.
(B) Hydrogen bonding network in the active site.
The sA-weighted 2Fo-Fc electron density map of
UMP is contoured at 1s. The loop closing onto
the substrate binding site is colored light green.
Asp317b (cyan) is contributed from the other
subunit to the active site. Hydrogen bonds to the
nucleotide and between protein side chains are
colored blue and magenta, respectively.
(C) Surface outlining the active-site volume. The
surface is colored green in hydrophobic areas.
Two protrusions are present at C5 and close to
C6. The side chain of Met371 and the 20-OH group
of UMP are not shown in this cut-away represen-
tation. A water molecule (red sphere) is present
in the UMP-complex but displaced by C5-substit-
uents.
(D) The nucleotide bound to OMPD can be
replaced by orthophosphate, glycerol, and a hy-
drophobic ion such as chloride, leading to a closed
conformation.Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved 83
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Crystal Structures of the Human OMPDTable 1. Data Collection and Refinement Statistics
Dataseta 2QCC ‘‘apo’’ 2QCD UMP 2QCE SO4
2, Glycerol, Cl 2QCF 5-FUMP 2QCG 5-BrUMP
Data Collection
Resolution range (A˚)b 50–1.84
(1.91–1.84)
50–2.03
(2.10–2.03)
50–1.42
(1.47–1.42)
50–1.22
(1.24–1.22)
50–1.75
(1.81–1.75)
100% criterion (A˚)c 1.88 2.04 1.50 1.22 1.90
Space group P212121 P21 C2221 C2221 P21
Cell dimensions (A˚, ) a = 62.0,
b = 75.9,
c = 119.5
a = 69.4,
b = 61.6,
c = 70.0, b = 112.7
a = 77.2,
b = 116.9,
c = 62.0
a = 76.8,
b = 115.5,
c = 61.4
a = 69.2,
b = 61.7,
c = 69.2, b = 113.0
Unique reflections 46969 (2878) 34716 (2961) 45102 (1381) 81404 (3900) 48733 (2344)
Multiplicity 10.8 (6.6) 6.2 (4.7) 6.7 (2.4) 6.4 (4.6) 2.5 (1.7)
Completeness (%) 94.3 (58.8) 98 (83.8) 84.4 (26.3) 99.8 (96.6) 90.0 (43.6)
Mosaicity () 0.65 0.66 0.57 0.47 0.83
Rsym (%)
d 0.094 (0.619) 0.095 (0.344) 0.079 (0.492) 0.083 (0.594) 0.081 (0.473)
Average I/s(I) 28.5 (2.0) 18.6 (3.9) 21.0 (1.7) 21.4 (2.5) 10.7 (1.2)
Refinement
Resolution range (A˚) 47.0–1.85
(1.90–1.85)
42.3–2.03
(2.08–2.03)
34.8–1.43
(1.47–1.43)
22.1–1.22
(1.25–1.22)
27.2–1.75
(1.93–1.75)
Rcryst (%)
e 19.7 (26.1) 14.9 (19.1) 14.5 (30.8) 12.1 (26.1) 16.7 (29.9)
Rfree (%)
e 25.7 (31.8) 19.5 (24.9) 16.5 (30.0) 14.8 (28.2) 20.2 (32.9)
Number of residues/waters 496/305 516/348 257/357 257/382 516/137
Coordinate error (A˚)f 0.126 0.103 0.036 0.023 —
Rmsd Bonds/Angles (A˚, ) 0.013/1.28 0.014/1.39 0.009/1.24 0.019/1.84 0.009/1.5
Ramachandran plot (%)g 90.8/8.2/0.0 90.3/8.7/0.0 91.1/8.9/0.0 91.1/8.9/0.0 89.8/10.0/0.2
Average B values (A˚2) 44.6 ± 5.2 26.9 ± 7.9 15.7 ± 8.7 13.2 ± 7.9 19.9 ± 7.6
Dataseta 2QCH 5-IUMP 2QCL OMP 2QCM 6-HMUMP 2QCN 6-IUMP
Data Collection
Resolution range (A˚)b 50–1.95
(2.02–1.95)
30–1.85
(1.92–1.85)
50–1.66
(1.72–1.66)
50–1.85
(1.89–1.85)
100% criterion (A˚)c 2.01 1.87 1.67 1.86
Space group P21 P21 C2221 P21
Cell dimensions (A˚, ) a = 69.6,
b = 62.0,
c = 70.6, b = 113.3
a = 69.5,
b = 61.6,
c = 70.3, b = 113.6
a = 77.4,
b = 116.6,
c = 61.9
a = 69.5,
b = 61.9,
c = 70.3, b = 114.0
Unique reflections 37157 (2610) 45421 (3963) 32717 (2466) 46040 (1575)
Multiplicity 3.1 (2.6) 3.8 (2.9) 4.6 (3.5) 4.9 (2.7)
Completeness (%) 92.1 (65.4) 97.2 (85.5) 97.3 (73.9) 99.1 (79.9)
Mosaicity () 1.81 0.99 0.92 0.60
Rsym (%)
d 0.101 (0.382) 0.062 (0.286) 0.050 (0.243) 0.053 (0.271)
Average I/s(I) 10.3 (2.6) 20.0 (3.4) 26.0 (4.3) 17.6 (2.9)
Refinement
Resolution range (A˚) 40.0–1.95
(2.00–1.95)
26.0–1.85
(1.90–1.85)
32.2–1.67
(1.71–1.67)
34.9–1.85
(1.90–1.85)
Rcryst (%)
e 22.1 (27.4) 17.2 (21.0) 14.1 (19.1) 15.6 (22.0)
Rfree (%)
e 26.8 (29.9) 21.3 (25.2) 15.9 (19.6) 18.8 (27.5)
Number of
residues/waters
510/229 512/406 257/309 514/410
Coordinate error (A˚)f 0.163 0.092 0.049 0.081
Rmsd Bonds/Angles (A˚, ) 0.009/1.25 0.015/1.50 0.012/1.42 0.015/1.47
Ramachandran plot (%)g 89.9/9.9/0.2 91.3/8.7/0.0 91.6/8.4/0.0 91.1/8.9/0.0
Average B values (A˚2) 31.2 ± 5.4 31.8 ± 6.8 28.1 ± 7.3 33.8 ± 8.284 Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved
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Crystal Structures of the Human OMPDMutagenesis studies on OMPD from S. cerevisiae and Metha-
nobacterium thermoautotrophicum have revealed a critical role
for residues Asp312 and Lys314 (see Table S1 for equivalence
numbering.) in catalysis (Miller et al., 2001). To probe the critical
function of Asp312 for human OMPD, we generated the
Asp312Asn mutant of human OMPD, which proved completely
inactive in the assay (Figure 1B). This observation is in contrast
to OMPD from M. thermoautotrophicum, where the correspond-
ing Asp70Ala mutant displayed residual decarboxylation activity
(Wu et al., 2002). As the structurally conservative change of a car-
boxylate to carboxamide is sufficient to render human OMPD
inactive, the Asp312Asn mutant allowed trapping of an OMPD-
OMP complex (see below) to pinpoint possible steps along the
decarboxylation mechanism.
Structure Description
The structure of human apo-OMPD was determined in space
group P212121 by molecular replacement and refined to a resolu-
tion of 1.84 A˚. OMPD belongs to the TIM-barrel family of en-
zymes (Sterner and Hocker, 2005) with a central barrel of eight
parallel b strands surrounded by a helices (Figure 2A). The active
site is situated at the C-terminal end of the b strands, with con-
tributions from side chains in the ba loops. Eight additional li-
gand-bound crystal structures of OMPD were determined at res-
olutions of 2.03 A˚ or better (Table 1). The maximum deviation
within these structures is 0.83 A˚ over 254 residues, indicating
only minor overall structural changes upon ligand binding. Simi-
lar to previously determined OMPD structures from S. cerevisiae
(Miller et al., 2000), Escherichia coli (Harris et al., 2000), Bacillus
subtilis (Appleby et al., 2000), and M. thermoautotrophicum (Wu
et al., 2000), the biologically active entity is a dimer. Each mono-
mer provides one critical residue (Asp317b) for the active site of
the other subunit (Figure 2B).
Loop Closure upon Ligand Binding and Substrate
Mimicry by Simple Compounds
The nucleotide binding site in OMPD can be conceptually di-
vided into three determinants for ligand recognition: the phos-
phate binding loop, residues interacting with the sugar moiety,
and residues fixing the nucleobase. OMPD was crystallized
from ammonium sulfate and crystals were cryoprotected with
glycerol, which led to inclusion of sulfate and glycerol in the bind-
ing pocket. The loop spanning residues 423–431 is disordered in
this structure. Upon cocrystallization of OMPD with UMP, this
loop becomes ordered by closing onto the bound nucleotide
(Figures 2B and 2C). Thus, the nucleobase is responsible for
loop closure. The uracil nucleobase (and all others examined
here) is locked in the syn conformation by three hydrogen bondsStructureto residues Ser372 and Gln430 (Figure 2B). The side chain of
Gln430 bridges the nucleobase and the phosphate moiety, pro-
viding further stabilization of the energetically disfavored syn
conformation. Catalysis requires the C5-C6 bond of the nucleo-
tide to face the catalytic residues Asp312 and Lys314 in the
active site, and this binding mode is conserved among all
OMPDs.
It has recently been demonstrated for S. cerevisiaeOMPD that
the substrate OMP can be mimicked by a phosphite anion and
1-orotidyl-b-D-erythrofuranoside (Amyes et al., 2005). This com-
posite substrate was decarboxylated 3$109-fold more slowly
than OMP, emphasizing the importance of the phosphate moiety
for anchoring the nucleotide (Sievers and Wolfenden, 2005).
When human OMPD was crystallized in the presence of chloride,
the resulting structure showed a closed conformation harboring
a tripartite mimic of a nucleotide by sulfate, glycerol, and a chlo-
ride ion (Figure 2D). The sulfate ion is an almost perfect mimic for
the phosphate part of the nucleotide. More importantly, glycerol
binds in a conformation practically identical to ribose and sat-
isfies all hydrogen bonds entertained by the 20- and 30-hydroxyl
groups of the ribose. Thus, sugars such as glycerol-3-phosphate
or erythrose-4-phosphate might bind to this site in vivo. The
ribose part might be replaced by smaller polyols during drug
design, as has been done in Herpes virostatica such as acyclovir
and ganciclovir.
The nucleotide mimic is completed by a chloride ion placed at
the position of the nucleobase. Three water molecules are re-
cruited to sites in hydrogen bonding distance to the chloride.
Two of these localize to the positions of the O2- and O4-oxygens
of UMP and form hydrogen bonds normally held by the nucleo-
base (Figure 2B). The negative charge and significant polarizabil-
ity of chloride is an unexpectedly efficient approximation for an
aromatic entity, which in the case of OMP also carries a negative
charge. With respect to catalysis, the dissection of the substrate
has limits, however. When OMPD was incubated with a mixture
of sulfate, glycerol, and orotate, no decarboxylation was ob-
served, probably due to an increase in substrate entropy. Taken
together, the observation that the active site of OMPD can be
filled with a variety of small molecules that approximate a bound
nucleotide demonstrates the potential to generate inhibitors by
using simple precursors such as polyols (as ribose mimics) and
electron rich compounds (as nucleobase mimics).
Probing the Active Site of OMPD
Using 5-Halo-UMP Derivatives
A surface representation of the active site cavity revealed a
pocket close to C5 of the nucleotide, which might be exploited
for drug design. To test this hypothesis, the crystal structuresa Structures of 5-FUMP, OMP, and 6-HMUMP are in complex with the D88N mutant.
b Values in parenthesis correspond to the highest resolution shell.
c The 100% criterion was calculated using SFTOOLS and represents the resolution in A˚ of a 100% complete hypothetical data set with the same
number of reflections as the measured data.
d Rsym = 100$ShSijIi(h)  < I(h) > j/ShSiIi(h), where Ii(h) is the ith measurement of reflection h, and < I(h) > is the average value of the reflection intensity.
e Rcryst =SkFoj  jFck /SjFoj, where Fo and Fc are the structure factor amplitudes from the data and the model, respectively. Rfree is Rcryst with 5% of test
set structure factors.
f Based on maximum likelihood.
g Calculated with PROCHECK. Numbers reflect the percentage amino acid residues in the core, allowed, and generous allowed regions, respectively.16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved 85
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Crystal Structures of the Human OMPDof UMP derivatives substituted with fluorine, bromine, and iodine
at C5 were determined. 5-fluorouracil (5-FU) is a metabolically
activated anticancer prodrug, which is used for treatment of
colorectal, stomach, and breast cancer tumors. OPRT activates
5-FU in vivo to 5-FUMP (Peters et al., 1986). The active metabo-
lite is thought to be 5-fluoro-dTMP, a covalent inhibitor of thymi-
dylate synthase that blocks DNA synthesis (Ichikawa, 2006).
Interestingly, 5-FUMP is also a weak inhibitor of OMPD (IC50 =
320 mM) (Table 2). The 1.2 A˚ resolution crystal structure of
5-FUMP in complex with Asp312Asn OMPD was determined
and showed that 5-FUMP is bound almost identically to the
product UMP (Figure 3A). Compared to the OMPD-UMP com-
plex, the fluorine atom displaces a water molecule in the vicinity
of Lys314, and the 5-FU nucleobase moves by 0.2A˚ toward this
newly created cavity. Small conformational changes are visible
in the adjoining side chains of OMPD. Thus, OMPD provides
a preformed, relatively rigid binding site for the nucleotide. The
fluorine atom of 5-FUMP points into a hydrophobic pocket lined
by residues Ile368, Met371, and Ile401 (Figure 2C). The pocket
was further probed by the halide derivatives 5-BrUMP and
5-IUMP to possibly obtain more potent inhibitors.
The crystal structure of 5-BrUMP in complex with OMPD
shows an intact nucleotide with the nucleobase slightly tilted to-
ward the hydrophobic pocket compared to UMP (Figure 3B). The86 Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reglycosidic torsion angle is smaller by 7 than that of UMP (121).
Similar to the case of 5-FUMP, there is no space for a water mol-
ecule near C5. The increased volume of bromine relative to fluo-
rine leads to a slight widening of the pocket lined by the b5a7 loop
and a remarkable 2.8 A˚ shift of the Nz atom of Lys314 away from
the nucleotide toward Asp317b, with which it forms a charged
hydrogen bond. The bromine atom is well accommodated in
this pocket, in agreement with a slightly lower IC50 value of 100
mM compared to 5-FUMP (320 mM). Lys314 stands out as the
most flexible residue in the OMPD active site.
Table 2. Approximate IC50 Values of Nucleotides for Human
OMPD at 25C
Inhibitor IC50 (mM)
UMP 400
6-HMUMP 450a
5-FUMP 320
5-BrUMP 100
5-IUMP 250
6-IUMP 10b
a No complete inhibition was achieved.
b Pseudo-IC50 value as 6-IUMP is a covalent inhibitor. Preincubation of
the samples was 2 hr.Figure 3. Environments of 5-Halo-Uridine
Nucleotides
(A) The sA-weighted omit electron density map of
5-FUMP is contoured at 1.5s. The orientation of
Asn312 is unambiguous, leading to a close con-
tact between the carboxamide nitrogen atom
and Nz of Lys281, which is probably uncharged.
(B) Conformational changes in the 5-BrUMP-
OMPD complex. Lys314 is displaced toward
Asp317b.
(C) The 5-IUMP-OMPD complex. The presence of
iodine was determined by using an anomalous
map (contoured at 4s). Iodine (large blue spheres)
was partially liberated and occupies an additional
site close to C6.
(D) 6-IUMP binds covalently to Nz of Lys314. A wa-
ter molecule, shown as a red sphere, occupies the
CO2 binding site below C6. The omit map at 1.5s
was obtained after truncation of Lys314 beyond
Cb and removal of the nucleotide.
(E) Stereo view of the nonplanar geometry of the
covalent linkage. Uracil is viewed side on.served
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is widened even further: residue Ser372 of the b5a7 loop is shifted
by 0.5 A˚ from its position in the UMP structure. This shift is
matched by the whole 5-IUMP nucleotide, apparently due to
the sterically demanding iodine atom at C5. The glycosidic tor-
sion angle of 5-IUMP is smaller by 20 relative to UMP to position
the iodine atom in the hydrophobic pocket formed by Ile368,
Met371, and Ile401. Lys314 adopts the same conformation as
in the UMP complex, and its Nzatom is located close to the iodide
atom, engaging in a short contact of 2.5 A˚ distance (Figure 3C).
The lack of flexibility in this area of the binding pocket may explain
the drop in apparent affinity of 5-IUMP (IC50 = 250 mM) compared
to 5-BrUMP. In summary, 5-halo-UMP derivatives are a novel
class of weak OMPD inhibitors with IC50 values comparable to
UMP (400mM). Further substitutions of UMP at C5 will be required
to fully assess the potential of this position for high affinity ligands.
Detection of a Possible CO2 Binding Site
A fortuitous result of the 5-IUMP-OMPD complex structure is di-
rect experimental evidence for the temporary CO2 binding site
shortly after decarboxylation. A small pocket next to C6 of the
pyrimidine base is present in human OMPD (bottom protrusion
in Figure 2C). OMPD from M. thermoautotrophicum has a similar
cavity that was speculated as a temporary CO2 binding site (Lee,
2004). An anomalous difference Fourier map revealed that
5-IUMP was partially cleaved at the C5-I bond and the liberated
iodine atom has relocated to the cavity close to C6 (Figure 3C),
congruent with the carboxylate group of OMP on the OMP-
OMPD complex (see below). Due to its polarizability and similar
size, iodine can readily mimic CO2, thus trapping the OMPD state
just prior to CO2 release. Halide ions (and also Xe) have been
used previously for pinpointing the binding sites of O2 (Cohen
et al., 2006; Duff et al., 2004; Hiromoto et al., 2006; Roeser
et al., 2007; Wade et al., 2004). The 5-IUMP-OMPD complex
suggests that this concept can be extended to CO2 and probably
to other small particles that are difficult to locate in crystal
structures.
6-IUMP as a Covalent Inhibitor of Human OMPD
Nucleotides modified at C6 have been used in previous mecha-
nistic studies of OMPD. Of these, 6-aza-UMP and 6-hydroxy-
UMP (BMP) are among the strongest, noncovalent inhibitors
with Kd values of 64 nM and 8.8 pM, respectively, for the M. ther-
moautotrophicum enzyme (Wu and Pai, 2002). Similar to OMP,
the base of BMP is negatively charged. The exceptionally high
affinity of BMP for OMPD was attributed to BMP acting as a tran-
sition state analog for a carbanion at C6 in a noncovalent mech-
anism (Levine et al., 1980). It therefore came as a surprise when
6-iodo-UMP (6-IUMP) was found to covalently bind to Plasmo-
dium falciparum OMPD (Bello et al., 2007), and we sought to
verify this property for human OMPD.
6-IUMP exhibited time-dependent inhibition of activity in
human OMPD. Whereas activity was unaltered immediately after
adding inhibitor, it was completely abolished after 12 hr preincu-
bation (data not shown). In a control experiment with 5-IUMP, full
long-term activity of OMPD was retained. Preincubation of OMPD
with increasing concentrations of 6-IUMP for 2 hr yielded a pseu-
do-IC50 value of 10 mM (Table 2), establishing that the inactivation
reaction has a half-life on this time scale. MALDI-TOF mass spec-Structurtrometry revealed covalentattachment of a UMP-moiety to OMPD
(Figure S2). The crystal structure of the human OMPD in complex
with 6-IUMP confirmed a covalent bond of Lys314 to C6 of UMP,
leading to a secondary amine (Figure 3D). Lys314 displays
a unique extended conformation that differs from all other
OMPD crystal structures (Figures 2–4). Asp312 forms a short 3 A˚
contact with the—presumably protonated—Nz atom. Although
the 1.85 A˚ resolution data is insufficient to unambiguously define
the Nz-C6 bond order, the electron density supports that Lys314
may connect to UMP via an enamine, not the less stable tauto-
meric imine. The enamine should be preferred over the imine
due to gain of aromaticity in the nucleobase. In contrast to the
5-IUMP complex, no iodine atom is found in the CO2 binding site,
but a water molecule occupies this position. A puzzling feature
is the nonplanarity of the Nz-C6 bond with the uridine ring system
(Figure 3E). The Nz-C6 torsion angle is 9 off from planarity, a fea-
ture not found in the Cambridge Structural Database (CSD). Even
more drastic nonplanarities are visible in the OMPD complexes
with OMP and 6-hydroxymethyl-UMP (6-HMUMP) described
below.
Apparent Substrate Distortion in 6-Substituted
UMP-OMPD Complexes
The absence of enzymatic activity of the Asp312Asn mutant
(Figure 1B) allowed trapping of an enzyme-substrate complex
in an almost wild-type-like environment (Figures 4A and 4B). In
comparison, for the M. thermoautotrophicum OMP-OMPD com-
plex a single mutation of Asp70 or Lys72 (Asp312 or Lys314 in
human OMPD) to alanine was insufficient, and the double mutant
Asp70Ala/Lys72Ala was required to trap an OMP-complex (Wu
et al., 2002).
Binding of OMP to OMPD induces the largest conformational
changes of any ligand studied here. A series of backbone and
side-chain movements drastically alters the hydrogen-bonding
network around OMP (Figure 4A). The region Asp312-Lys314
in the b3-strand moves as a rigid body by ca. 1 A˚ perpendicular
to the strand axis. The OMP carboxylate group displaces the Ca
atom of Asn312 by 1.1 A˚ relative to the UMP complex, with a con-
comitant 90 rotation around the c2 angle of the side chain. This
movement of Asn312 induces a concerted flip of the His283 and
Asp259 side chains. The imidazole group of His283 moves by 3A˚
from its position in the UMP complex and no longer binds to the
ribose moiety but to Ser257. Asp259 moves out of the way and
reorients its side chain toward the solvent. The corresponding
Ca atoms of His283 and Asp259 move by almost 1 A˚. The
OMP nucleotide is shifted by 0.4 A˚ toward Gln430 and Ser372
compared to the UMP-complex. This binding mode of the nucle-
obase is not unlike that of 5-BrUMP and 5-IUMP, which are also
shifted ‘‘upwards’’ with respect to the UMP state. Apparently,
additional bulk at the C5-C6 side of the pyrimidine ring lifts the
nucleotide slightly out of the active site.
Strikingly, the C6 bond to the carboxylate group is not in plane
with the nucleobase but tilted by ca. 36 toward Lys281 to form
a charged hydrogen bond with this lysine (Figures 4A and 4B). A
survey of 29 orotid-containing structures in the CSD did not pro-
duce any conformation with such a tilt, but the C6-carboxylate
bond is always in plane with the aromatic system. A tilted OMP
was observed in the M. thermoautotrophicum OMPD double
mutant Asp70Ala/Lys72Ala (Wu et al., 2002), indicating that thee 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved 87
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in the wild-type enzyme.
The chemical nature of this unusual geometry is currently un-
known, but two possibilities are suggested from the OMP-OMPD
crystal structure: (1) protonation of the C6 atom by Asp317b,
which would render C6 sp3 hybridized and localize a positive
charge at C5 or (2) substrate deformation by nearby residues.
The side chain of Asp317b from the other subunit of the OMPD
Figure 4. Substrate Binding to OMPD
(A and B) Stereo representation of the Asp312Asn
OMPD-OMP complex showing a bent carboxylate
group.
(C and D) Stereo representation of the Asp312Asn
6-HMUMP-OMPD complex. The hydroxymethyl
group is also bent out of plane, indicating that
electrostatic repulsion by Asp317b is not respon-
sible for substrate deformation.
dimer is located perpendicular to and to-
ward the C5-C6 bond of the ring. Given
the large differences in the pKa values
of Asp317b and C6 of a nucleotide, pro-
tonation of C6 must be energetically dis-
favored, but would render C6 sp3-hybrid-
ized and immediately explain the
deviation from planarity. Alternatively,
the short distances of 3.8 A˚ to the C6
atom and 5 A˚ to the OMP carboxylate
group might induce a distortion via elec-
trostatic repulsion. This hypothesis was
tested by using 6-HMUMP, which lacks
both an oxygen atom and a negative
charge compared to OMP. 6-HMUMP is
not a substrate but a weak inhibitor of
OMPD (Table 2). The crystal structure of
6-HMUMP in complex with Asp312Asn
OMPD was determined to a resolution
of 1.66 A˚ and indeed reveals a kinked nu-
cleotide (Figures 4C and 4D). While the
deviation of 15 is not as pronounced as
in OMP (36), the electron density is in-
compatible with a planar bond between
C6 and the hydroxymethyl group, arguing
against electrostatic repulsion. The hy-
droxymethyl group of 6-HMUMP is nicely
integrated into the hydrogen bonding
network of the enzyme (Figure 4D), leav-
ing no obvious hint as to which residue
might be responsible for the distortion
of the nucleotide. However, the promi-
nent backbone and side-chain move-
ments in the OMP-OMPD complex are
absent in the 6-HMUMP-OMPD com-
plex, strongly indicating that the negative
charge of OMP induces these rearrange-
ments. In conclusion, the observation of
a distorted nucleotide in the complexes
of human OMPD with OMP, 6-IUMP,
and 6-HMUMP, as well as in the OMP complex of the M. ther-
moautotrophicum OMPD double mutant Asp70Ala/Lys72Ala
(Wu et al., 2002), establishes this induced change in nucleotide
structure as a salient feature of OMPDs. Both protonation and
genuine strain are possible, yet energetically demanding mech-
anisms for nucleotide deformation. With the currently available
crystal structures, it is impossible to decide between protonation
and ground state destabilization. Design of nucleotides with88 Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved
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at C6 will be required to answer this question.
DISCUSSION
The crystal structure of human OMPD described here repre-
sents, to our knowledge, the first example for a mammalian ho-
molog of these proficient enzymes. Structures of OMPDs from
micro-organisms determined previously are dimers, though the
active site architectures can differ significantly (Appleby et al.,
2000; Harris et al., 2000; Miller et al., 2000; Wu et al., 2000).
The human OMPD dimer provides a structural explanation for
the orotic aciduria-inducing Gly429Arg variant of UMPS (Suchi
et al., 1997). Gly429 is located in a loop closing onto the phos-
phate part of the nucleotide and is also part of the dimer inter-
face. Mutation of this residue to arginine impedes dimer forma-
tion. If the loop changed its conformation, Gln430 could not
bridge the nucleobase and the phosphate part of the nucleotide,
thereby disrupting the binding site. Thus, the Gly429Arg muta-
tion has both a structural and functional effect, leading to inactiv-
ity of OMPD.
A Framework for Species-Specific
OMPD Inhibitor Design
Potential pitfalls of OMPD inhibition include apparent higher tox-
icity effects when blocking the pyrimidine pathway compared to
the purine pathway (Christopherson et al., 2002), possible inter-
ference with clonal expansion of immune cells (Quemeneur
et al., 2004), and the danger of induced orotic aciduria. Still,
OMPD inhibitors could be useful in complementing the current
arsenal of anticancer drugs and for short-term treatment of
infections.
The human OMPD structure can serve as a framework for
engineering potent, yet specific inhibitors. Cross-species reac-
tivity must be minimal in treatment of infections. 6-iodouridine
has been found to exhibit antimalarial activity and was ca. 100-
fold more active on Plasmodium isolates than on CHO cells
(Bello et al., 2007). 6-iodouridine is presumably phosphorylated
in vivo and acts as a covalent inhibitor of OMPD via the cata-
lytic lysine (Bello et al., 2007). Despite a low sequence identity
of <20% with P. falciparum OMPD, the same crosslink is pos-
sible with human OMPD. Hence, the therapeutically attractive
mode of ‘‘suicide’’ inhibition by 6-iodouridine-based nucleo-
tides may pose problems due to insufficient species specific-
ity. More specific inhibitors might be designed by using the
pockets identified close to C5 and C6 of the nucleotide. The
weak inhibition of OMPD by the 5-halo-UMP derivatives is
a first step in this direction. Using small, hydrophobic, and
more flexible substituents at C5 should circumvent the cur-
rently low affinity of the 5-halo-UMPs. The CO2 binding cavity
could also be exploited for inhibitor design, e.g., by introducing
a Csp3 carbon at C6. In such a chiral compound, the C6-sub-
stituent would point toward the CO2 binding site, similar to the
kinked geometry in the OMP-OMPD and 6-HMUMP-OMPD
complexes. As a long-term goal, synthesis of small, hydro-
phobic compounds that are converted by OPRT to the inhibi-
tory nucleotides could enable alternative treatments for both
malaria and cancer.StructureCatalytic Ambivalence of OMPD
on 6-Substituted Nucleotides
OMPD engages in nonnative reactions such as covalent modifi-
cation by 6-IUMP (Figures 3D and 5A) (Bello et al., 2007) and hy-
drolysis of 6-cyano-UMP to BMP (Figure 5B) (Fujihashi et al.,
2005). The C6 atom should be more electrophilic in 6-IUMP
than C5 in 5-IUMP due to the electronegativity of the glycosidic
N1. This consideration is confirmed by the fact that only 6-IUMP
but not 5-IUMP forms a stable covalent complex with Lys314.
Overlay of the nine crystal structures reveals Lys314 as the
most flexible residue in the active site, with the Nz atom covering
distances of up to 2.5 A˚. This flexibility of the nucleophile is
important for an orthogonal attack on C6 since the substrate is
immobilized in the binding pocket. Iodine is known as an unspe-
cific substituent that can be readily displaced by nucleophiles
such as azide (Poduch et al., 2006). It thus seems that 6-IUMP
is a poor analog for OMP and activation of C6 together with
the good leaving group iodide provokes a nonnative reaction
with Lys314 acting as a nucleophile.
A similar case can be made for 6-cyano-UMP, which is short-
term stable in presence of S. cerevisiae OMPD (Callahan et al.,
2006), but slowly hydrolyzed to BMP with a half-life of ca. 24 hr
(Fujihashi et al., 2005). Preliminary data show that this nucleotide
is also degraded by human OMPD (not shown). A mechanism
with Lys314 acting as a nucleophile can be formulated (Fig-
ure 5B) but leaves open the question why 6-cyano-UMP does
not covalently bind to OMPD, as does 6-IUMP, but is hydrolyzed
to BMP. An explanation is possible using covalent mechanisms:
iodide is a better leaving group than cyanide. The slow elimina-
tion of cyanide from a tetrahedral intermediate may be outplayed
by neighboring group participation of the lysine Nz atom. Forma-
tion of a reactive imine or iminium ion would be followed by
hydrolysis to yield BMP. The required water molecule is already
present in the CO2-binding pocket at a distance of 3.1 A˚ to the C6
atom (Figure 3D). Taken together, the flexibility and nucleophilic
properties of the catalytic lysine residue in human and P. falcipa-
rum OMPD give rise to reactions with nucleotides that are suffi-
ciently activated at C6. These reactions are clearly nonnative but
demonstrate the nucleophilic potential of the catalytic lysine
residue.
Activation of C6 by an electronegative substituent such as
iodo-, cyano-, and carboxylate invites a covalent attack at C6 in-
stead of C5. The outcome of a nucleophilic attack at this carbon
atom depends on the nature of the leaving group. If heterolytic
fission of the bond at C6 is required, an anion such as iodide
or cyanide is released. For decarboxylation, fission must occur
at the carboxylate carbon atom to generate CO2. Such a reaction
requires a nucleophilic attack at C5, not C6, which raises the
question as to whether OMP-decarboxylation can indeed pro-
ceed through a covalent intermediate at C5.
Could OMP-Decarboxylation
Proceed via a Covalent Mechanism?
Kinetic 13C, 15N and solvent isotope effects as well as 13C-NMR
have been used to pinpoint intermediates or to rule out variants
of OMPD mechanisms (Acheson et al., 1990; Ehrlich et al., 1999;
Rishavy and Cleland, 2000; Smiley et al., 1991). If the bond order
of an atom changes in the rate-limiting step, substitution of an
isotope for that atom should result in a rate change. For instance,16, 82–92, January 2008 ª2008 Elsevier Ltd All rights reserved 89
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nisms of Substitution at C6 via Covalent
Intermediates
(A and B) In the presence of a 6-substituent X that
can be eliminated as X, such as cyano or iodine,
Lys314 may attack directly at C6. The covalent
intermediate is resolved in two ways leading to
either substitution by Lys314 (covalent complex)
or by water (formation of BMP, which will further
ionize).
(C) A 6-substituent that requires cleavage of the
C6-X bond at X, such as carboxylate, Lys314
may attack at C5, although this position is not as
electrophilic as C6. Attack at C6 would lead to
an unproductive intermediate.enolization to a quaternary ammonium ion at N1 and formation of
a stabilized ylide zwitterion as a noncovalent alternative of the
OMPD mechanism (Beak and Siegel, 1976) was excluded based
on a lacking 15N kinetic isotope effect (Rishavy and Cleland,
2000). 13C kinetic isotope and D2O solvent isotope effects for
E. coli OMPD showed that decarboxylation is rate limiting, that
protonation must occur prior to decarboxylation, and that a con-
certed mechanism is impossible (Ehrlich et al., 1999). A covalent
mechanism has been excluded for S. cerevisiaeOMPD based on
the requirement for all other steps to be much faster than the
rate-limiting decarboxylation (Smiley et al., 1991). However,
this seems possible given the low stability of model compounds
for decarboxylation: model chemistry of nucleophilic Michael ad-
dition to a,b unsaturated carboxylic acids was used to address
the feasibility of a covalent mechanism for OMPD (Silverman
and Groziak, 1982). For instance, bisulfite reacts with OMP sur-
rogates at C5 (N,N-dimethyl-6-acetyluracil and N,N-dimethylor-
otaldehyde) via a Michael addition, leading to unstable and
therefore not rate-limiting products. This observation is a testi-
mony for rapid and reversible addition of Lys314 to C5 of OMP
but points to the inherent difficulty of trapping such an interme-
diate.
It is quite possible that in OMPD a rapid and reversible attack
of OMP occurs at both C5 and C6, but only in case of C5 will the
reaction proceed toward decarboxylation, i.e., the substrate it-
self imposes regiospecificity. A fast, nonrate-limiting equilibrium
shifted to the educt side would produce neither an isotope effect
nor a significant chemical shift in a 13C-NMR spectrum, which
indeed have not been found (Acheson et al., 1990). Therefore,
a covalent mechanism for decarboxylation appears to be in
unison with the currently available biochemical, structural, and
kinetic data on OMPDs.
The simplicity of a covalent mechanism similar to that of thymi-
dylate synthase (Carreras and Santi, 1995) is intriguing. Such
a mechanism, which does not require high-energy intermediates,
has been suggested long ago (Silverman and Groziak, 1982) and
would involve Michael addition of Lys314 at C5 to generate a tet-
rahedral intermediate at C6 via protonation, followed by elimina-
tion of CO2 and regeneration of the enzyme (Figure 5C). Of
course, the fact that Lys314 can attack C6 does not prove that at-90 Structure 16, 82–92, January 2008 ª2008 Elsevier Ltd All rights retack on C5 is also possible. However, comparison of the OMPD
complex structures suggests Lys314 to be flexible enough to
also reach C5 for nucleophilic attack. Direct proof requires trap-
ping of a covalent intermediate by using suitably designed nucle-
otides. Design of suitable substrate analogs and mutants that are
either inactive or retain a low residual activity was vital to demon-
strate the covalent mechanism in hen egg white lysozyme (Voca-
dlo et al., 2001), and a similar approach should be able to estab-
lish the prevailing mechanism for OMPD as well (Callahan and
Miller, 2007).
EXPERIMENTAL PROCEDURES
Nucleotides
5-bromo-UMP (5-BrUMP) and 5-iodo-20desoxy-UMP (5-IUMP) were pur-
chased from Jena Bioscience. OMP was purchased from Sigma. The synthe-
ses of all other nucleotides are described in the Supplemental Data.
Protein Production, Purification, Crystallization,
and Enzymatic Activity
OMPD was cloned, produced, purified, and crystallized as described (Witt-
mann and Rudolph, 2007). For cocrystallization experiments, 1 ml of an aque-
ous ligand solution at 10 mM was applied to a sitting drop plate (Hampton) and
air dried. Addition of 1 ml 5 mg/ml apo-OMPD redissolved the ligand and
formed the respective OMPD-nucleotide complex without dilution. For ab-
sorption measurements, OMPD in 20 mM HEPES/NaOH (pH 7.4) was equili-
brated at 25C and the decrease in A285 (D3 = 1650 M1 cm1) after addition
of saturating concentrations of OMP was monitored. The initial slopes of the
steady-state reactions were plotted against [OMPD] and evaluated as a simple
Michaelis-Menten system assuming equal and independent activities of the
subunits.
Data Collection, Structure Determination, and Refinement
Data were collected at 100 K and reduced with the HKL programs (HKL
research). Crystals appeared in space groups P212121, P21, and C2221 with
Matthews coefficient VM = 2.4A˚
3/Da and solvent content 48%. Crystals of
the 5-BrUMP-OMPD complex were pseudomerohedrally twinned, which
was described in detail previously (Wittmann and Rudolph, 2007). All other
crystals used here were untwinned. The structure was determined by molec-
ular replacement using the polyserine coordinates of PDB ID 1KM6. All other
structures were determined by using the first OMPD structure as the starting
model. Models were built in COOT (Emsley and Cowtan, 2004) and refined
with REFMAC5 (CCP4, 1994), except for the 5-BrUMP-OMPD complex, which
was refined in CNS by using the least-squares protocols for twinned dataserved
Structure
Crystal Structures of the Human OMPD(Bru¨nger et al., 1998; Wittmann and Rudolph, 2007). The same set of 5% of re-
flections was reserved for Rfree crossvalidation in all structures (Bru¨nger, 1992).
Statistics are summarized in Table 1. Figures were created with Bobscript
(Esnouf, 1997) and rendered with Raster3D (Merritt and Murphy, 1994) or
PyMol (http://www.pymol.org/).
Supplemental Data
Supplemental Data include data on the UV-based enzyme assay, mass spec-
tra, equivalence numbering table, and detailed chemical syntheses and are
available at http://www.structure.org/cgi/content/full/16/1/82/DC1/.
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Accession Numbers
The coordinates and structure factors have been deposited in the Protein Data
Bank (accession codes 2QCC, 2QCD, 2QCE, 2QCF, 2QCG, 2QCH, 2QCL,
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